← Back to codex

Glandokort

Aliases: Adrenal peptide bioregulator

Last verified: 2026-09-23

Research chemicalLimited evidenceBioregulatorsLow interest

The short version

An oral adrenal peptide complex — adrenal and stress-response support. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Russian series. Status: research chemical. Supplement status.

Identity & type

Molecular type
bioregulator
Origin
An oral adrenal peptide complex — adrenal and stress-response support.

Mechanism of action

Adrenal peptides; steroidogenesis modulation per the bioregulator model.

not confirmed in humans

Dosing & routes

Official / clinical context

No approved official document exists for Glandokort. Any protocols mentioned are to be read as information, not as a recommendation.

Regulator-approved labeling and published study designs — never a recommendation.

Community-reported practice

1–2 capsules/day, courses. An adrenal bioregulator: energy and stress-response support reported in the elderly; weak documentation.

Unverified self-reports. Not medical advice. Not endorsement.

Expected effects (community)

An adrenal bioregulator: energy and stress-response support reported in the elderly; weak documentation.

Protocol — official vs community

Official / label

No approved protocol exists. Glandokort is an oral adrenal peptide complex (cytomedin class) sold as a supplement; no registered drug product in any major market.

Duration:

Supplement status only; the steroidogenesis-modulation claim rests on the standard bioregulator evidence profile.

Community (anecdotal)

1–2 capsules daily for 10–30 days; oral peptide uptake is unproven.

Cycle:
1–2 courses per year.
Break:
Months between courses.

The capsule regimen mirrors the shared bioregulator course structure; only the adrenal/stress-response targeting claim distinguishes it from the other oral cytomedins.

Human evidence

Human data are limited: small trials or case-series reports exist, without large randomized studies. Russian series.

Preclinical evidence

Russian series.

Known risks

  • None reported.characterized

Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.

Unknowns & evidence gaps

  • Long-term human safety
  • Optimal dose and pharmacokinetics

Frequently asked questions

References

Systematic references are being expanded; verify sources directly before any decision.